EXETER, England, September 26 /PRNewswire/ -- Mobious Detection, in association with Mobious Genomics is pleased to announce that it has successfully demonstrated a prototype version of its accelaffin technology to a leading global diagnostics company.
The test identified a bacterial sample, prepared by the diagnostics company at a concentration of 25 bacteria/ml, within 40 seconds (i.e. within the minute specified by Mobious). At present, conventional immunoassays take between six and 48 hours to positively identify specific bacteria at such low concentrations. The test is not only much faster than conventional tests but due to the shorter integration time the system is also more sensitive.
Daniel Densham, Managing Director of Mobious Detection, owner of the Accelaffin(TM) technology and also Managing Director of associated company Mobious Genomics commented: “We are very pleased to have successfully demonstrated our groundbreaking technology to a major diagnostics player. I am confident that this is the first step in a commercialisation program that will lead to rapid global uptake of the technology across a broad range of fields”.
The Accelaffin(TM) technology is applicable to immunoassays as well as direct genetic tests. Therefore it can provide high sensitivity tests for diseases such as HIV, Hepatitis, MRSA, Bird flu as well as markers such as those for stroke or heart attack from a variety of sample types in a minute or less.
Notes to Editors
Background
Mobious Genomics is pioneering the development of fundamentally new technologies in the fields of genetic analysis and proteomics.
By unifying biological molecular systems and artificial nanostructures, Mobious has created a range of next generation diagnostic and research tools, able to materially outperform current platforms at a fraction of the cost.
The group’s research has resulted in new technologies and IP in such fields as single molecule sequencing, sequencing by synthesis, ultra highly multiplexed real-time PCR and affinity acceleration for biochips.
Mobious believes that its technology has the potential to help transform the acquisition and use of genetic knowledge in the global healthcare and detection industries.
Mobious Genomics Ltd
CONTACT: For more information please contact: Daniel Densham, MobiousGenomics +44-(0)8700-112-500, dhd@mobious.com
